C B Wulff1,2, T A Gerds3, L Rode1,4, C K Ekelund1, O B Petersen5, A Tabor1,2. 1. Center of Fetal Medicine, Department of Obstetrics, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 2. Faculty of Medicine and Health Sciences, University of Copenhagen, Copenhagen, Denmark. 3. Section of Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark. 4. Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte Hospital, Copenhagen, Denmark. 5. Fetal Medicine Unit, Department of Obstetrics and Gynecology, Aarhus University Hospital, Skejby, Denmark.
Abstract
OBJECTIVE: To assess prospectively the risk of fetal loss associated with chorionic villus sampling (CVS) and amniocentesis (AC) following combined first-trimester screening (cFTS) for Down syndrome. METHODS: This was a nationwide population-based study (Danish Fetal Medicine Database, 2008-2010) including 147,987 women with singleton pregnancy who underwent cFTS. Propensity score stratification was used to assess the risk of fetal loss with and without invasive testing. Analyses were performed between 3 and 21 days after cFTS for CVS and between 28 and 42 days after cFTS for AC. Results are reported as average risk differences with 95% CIs. RESULTS: The risks of miscarriage and stillbirth were not higher in women exposed to CVS or AC compared with unexposed women, independent of the analysis time-point. The average effect of CVS on risk of miscarriage was -0.08% (95% CI, -0.64; 0.47) at 3 days and -0.21% (95% CI, -0.58; 0.15) at 21 days after cFTS, while the effect on risk of stillbirth was -0.18% (95% CI, -0.50; 0.13) at 3 days and -0.27% (95% CI, -0.58; 0.04) at 21 days after cFTS. Regarding the effect of AC on risk of miscarriage, the analysis at 28 days after cFTS showed an average effect of 0.56% (95% CI, -0.21; 1.33), while the effect on risk of stillbirth was 0.09% (95% CI, -0.39; 0.58) at 42 days after cFTS. CONCLUSION: Neither CVS nor AC was associated with increased risk of miscarriage or stillbirth. These findings indicate that the procedure-related risk of CVS and AC is very low.
OBJECTIVE: To assess prospectively the risk of fetal loss associated with chorionic villus sampling (CVS) and amniocentesis (AC) following combined first-trimester screening (cFTS) for Down syndrome. METHODS: This was a nationwide population-based study (Danish Fetal Medicine Database, 2008-2010) including 147,987 women with singleton pregnancy who underwent cFTS. Propensity score stratification was used to assess the risk of fetal loss with and without invasive testing. Analyses were performed between 3 and 21 days after cFTS for CVS and between 28 and 42 days after cFTS for AC. Results are reported as average risk differences with 95% CIs. RESULTS: The risks of miscarriage and stillbirth were not higher in women exposed to CVS or AC compared with unexposed women, independent of the analysis time-point. The average effect of CVS on risk of miscarriage was -0.08% (95% CI, -0.64; 0.47) at 3 days and -0.21% (95% CI, -0.58; 0.15) at 21 days after cFTS, while the effect on risk of stillbirth was -0.18% (95% CI, -0.50; 0.13) at 3 days and -0.27% (95% CI, -0.58; 0.04) at 21 days after cFTS. Regarding the effect of AC on risk of miscarriage, the analysis at 28 days after cFTS showed an average effect of 0.56% (95% CI, -0.21; 1.33), while the effect on risk of stillbirth was 0.09% (95% CI, -0.39; 0.58) at 42 days after cFTS. CONCLUSION: Neither CVS nor AC was associated with increased risk of miscarriage or stillbirth. These findings indicate that the procedure-related risk of CVS and AC is very low.
Authors: Mathias Ehrich; John Tynan; Amin Mazloom; Eyad Almasri; Ron McCullough; Theresa Boomer; Daniel Grosu; Jason Chibuk Journal: Genet Med Date: 2017-06-15 Impact factor: 8.822
Authors: Katharina Klages; Sudip Kundu; Joachim Erlenwein; Michael Elsaesser; Peter Hillemanns; Alexander Scharf; Ismini Staboulidou Journal: J Pain Res Date: 2017-03-13 Impact factor: 3.133
Authors: Sara Perlado; Ana Bustamante-Aragonés; Marta Donas; Isabel Lorda-Sánchez; Javier Plaza; Marta Rodríguez de Alba Journal: PLoS One Date: 2016-04-14 Impact factor: 3.240
Authors: Bénédicte Buffin-Meyer; Julie Klein; Loes F M van der Zanden; Elena Levtchenko; Panogiotis Moulos; Nadia Lounis; Françoise Conte-Auriol; An Hindryckx; Elke Wühl; Nicola Persico; Dick Oepkes; Michiel F Schreuder; Marcin Tkaczyk; Gema Ariceta; Magdalena Fossum; Paloma Parvex; Wout Feitz; Henning Olsen; Giovanni Montini; Stéphane Decramer; Joost P Schanstra Journal: Clin Kidney J Date: 2019-09-26